Its versatility has driven widespread adoption across U.S. hospitals, including intensive care units, emergency departments, neonatal care and transport settings.

Aerogen Solo addresses a critical healthcare challenge with significant economic implications: the effective, consistent and safe delivery of inhaled therapies for patients with acute and chronic respiratory compromise. Respiratory disease places a major burden on healthcare systems globally, including in the United States. Technologies that improve delivery efficiency, reduce treatment variability and standardise best practice support better patient outcomes while contributing to healthcare system efficiency and sustainability.

Aerogen is currently expanding its manufacturing capacity in Shannon, Ireland, investing in advanced equipment, duplicating production lines and qualifying additional suppliers. These investments strengthen supply chain resilience, reduce dependency risk for U.S. healthcare providers and ensure consistent availability for millions of patients worldwide. Continuous process optimisation and energy-efficient manufacturing reinforce sustainability while maintaining the highest quality and regulatory standards.

Aerogen’s clinical and commercial impact is amplified through their global clinical education platform, delivered through integrated teams in Ireland and the United States. In 2025 alone, Aerogen educated over 50,000 clinicians globally, accelerating evidence-based adoption and embedding Aerogen Solo into routine clinical practice across ICU, emergency, neonatal and transport environments.